Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ImmunoGen, Inc.

< Previous 1 2 Next >
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Canaccord Genuity 43rd Annual Growth Conference
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Proposed Public Offering of Common Stock
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Reports Recent Progress and 2022 Financial Results
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.